This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Not applicable	<p><i>In vitro</i> and mouse studies suggest that F77, a mAb targeting a glycolipid prostate marker, could help treat prostate cancer. The mAb was isolated from mice injected with human prostate cancer cells. <i>In vitro</i> studies showed that F77 targeted 112 of 116 primary prostate cancer samples and 29 of 34 metastatic tumor samples. Exposing prostate cancer cells to F77 led to cell death and complement- and antibody-dependent cytotoxicity. In mice transplanted with prostate cancer cells, F77 inhibited tumor growth compared with a murine IgG or vehicle control. Next steps include humanizing the antibody.</p> <p>SciBX 3(3); doi:10.1038/scibx.2010.84 Published online Jan. 21, 2010</p>	Provisional patent application filed for F77 and modified antibody molecules to treat and detect prostate cancer in the U.S.; available for licensing	<p>Zhang, G. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 28, 2009; doi:10.1073/pnas.0911397107</p> <p>Contact: Mark Greene, University of Pennsylvania School of Medicine, Philadelphia, Pa. e-mail: green@reo.med.upenn.edu</p>